PharmaLife

🎉 FDA greenlights Attruby™ (acoramidis) for treating transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). This oral treatment aims to reduce cardiovascular death & hospitalization. Expected launch soon with an annual cost of $244K. More details on its promising impact from our partner VativoRx, LLC! https://lnkd.in/esKEc3s3 #HeartHealth #ATTRCM

🚨 #FDA approves Bimzelx® (bimekizumab-bkzx) for moderate-to-severe hidradenitis suppurative (HS), its fifth indication. Key trials show significant symptom reduction in HS patients. Bimzelx targets IL-17A and IL-17F, improving patient outcomes. More details from our partner VativoRx, LLC: https://lnkd.in/eukRgtXa #Dermatology #HidradenitisSuppurativa

🚨 FDA approves Ziihera® (zanidatamab-hrii) for HER2+ biliary tract cancer (BTC) in adults with prior treatment. First HER2-targeted therapy for BTC, showing 52% response rate! Launch info coming Dec. 11. More info from our partner VativoRx, LLC: https://lnkd.in/e2i_KC7N #BiliaryCancer #FDAApproval #Ziihera

🚀 Breakthrough in leukemia treatment! #FDA approves Syndax Pharmaceuticals' Revuforj® (revumenib), the first menin inhibitor for R/R acute leukemia with KMT2A translocation in adults & children aged 1+. Launch this Nov. with a $474K annual cost. More from our partner VativoRx, LLC: https://lnkd.in/e7N9yFnV #LeukemiaTreatment #Revuforj

FDA issues Complete Response Letter to Intercept for Ocaliva®, extending review due to unclear clinical benefits in primary biliary cholangitis (PBC). Further steps are in discussion as Ocaliva continues under accelerated approval. Additional updates from our partner VativoRx, LLC here: https://lnkd.in/eC-aNyBz #FDAUpdate #PBC

🧬 FDA grants accelerated approval to Kebilidi™ by PTC Therapeutics! This pioneering gene therapy for AADC deficiency is the first to be directly administered to the brain, promising new treatment horizons. More details from our partner VativoRx, LLC here: https://lnkd.in/eAM6fkgh #GeneTherapy #AADCDeficiency

FDA greenlights Aucatzyl® by Autolus Therapeutics for adult r/r B-ALL. First CD19 CAR T-cell therapy approved w/o REMS, offering new hope in leukemia treatment. Read more from our partner VativoRx, LLC: https://lnkd.in/eH2-m5FM #LeukemiaCare #CARTtherapy

FDA approves Emrosi™ (minocycline hydrochloride 40mg) for inflammatory lesions of rosacea in adults. A new oral option showing superiority over Oracea® & placebo in clinical trials. Expected launch Q1-Q2 2025! More info from our partner VativoRx, LLC: https://lnkd.in/eTze59Qu #RosaceaTreatment #SkinHealth

FDA greenlights Orlynvah™ (sulopenem etzadroxil & probenecid), a new oral penem antibiotic, for treating uncomplicated UTIs in adult women with limited treatment options. A pivotal advance in combating resistant infections! More updates from our partner VativoRx, LLC here: https://lnkd.in/eRGR9RSe #HealthNews #UTITreatment

🌟 FDA approves a new use for Botox® Cosmetic for smoothing platysma bands on the neck, enhancing jawline definition. First of its kind for this area beyond the face! More from our partner VativoRx, LLC: https://lnkd.in/ezby5jdC #BotoxCosmetic #Skincare